Forecast

The analysts' average price target is +13,17€ (+26,27%). The median is +7,73€ (−25,89%).

Buy	11
Hold	1
Sell	0

News Go to news feed

Abcellera Biologics reaches 52-week high of $12.15 after clinical success and financing move

Abcellera Biologics shares rose to a 52-week high of $12.15 and are up about 172.5% year-to-date. Despite the rally, InvestingPro rates the stock as overvalued and the RSI indicates an overbought territory. In Q2 the company missed expectations with an adjusted loss of $0.18 per share and revenue of $4.1 million, but highlighted a strong cash position and announced a guaranteed public offering of $200 million. Positive top-line results from the Phase 2 study of ABCL635 prompted Truist to raise its price target from $12 to $30 while keeping a "Buy" rating. » More on de.investing.com
Abcellera Biologics stock reaches 52-week high at $11.51

Abcellera Biologics shares climbed to a 52-week high of $11.51 after gaining 148% over the past year and 259% in the past six months. An InvestingPro analysis classifies the stock as overvalued and points to an overbought condition based on the RSI. In Q2 the company reported an adjusted loss of $0.18 per share and revenue of $4.1 million, both below analysts' expectations. AbCellera announced a guaranteed public offering of $200 million and simultaneously reported positive Phase‑2 results for ABCL635, after which Truist significantly raised its price target. » More on de.investing.com
AbCellera plans public offering of $200 million at $9.75 per share

AbCellera is offering 17,435,897 common shares at $9.75 per share, as well as pre-funded warrants to purchase up to 3,076,926 shares at $9.74999 each, and expects gross proceeds of approximately $200 million before fees. The closing is expected to occur on Friday, subject to customary conditions. Net proceeds are intended to fund research, development and clinical advancement of the internal pipeline, including the ABCL635 program, as well as working capital and general corporate purposes. » More on de.investing.com

Financials

In the last quarter, AbCellera had revenue of 3,55 Mio€ and net profit of −48,57 Mio€

(EUR)	Jun 2026	YoY
Revenue	+3,55 Mio	75,52%
Gross profit	+3,55 Mio	75,52%
Net profit	−48,57 Mio	64,84%
EBITDA	−36,39 Mio	10,44%

Fundamentals

Metric	Value
Market capitalization	+2,78 Mrd€
Number of shares	305,38 Mio
52-week high/low	+10,44€ - +2,36€
Dividends	No
Beta	1,19
P/E ratio	−19,65
PEG ratio	+36,17
P/B ratio	+3,62
P/S ratio	+48,96

Company profile

AbCellera Biologics Inc. entwickelt eine Plattform zur Entdeckung von Antikörpern. Seine auf künstlicher Intelligenz basierende Plattform zur Entdeckung von Antikörpern durchsucht und analysiert die Datenbank des natürlichen Immunsystems, um Antikörper zu finden, die als Arzneimittel entwickelt werden könnten. Zum 31. Dezember 2021 verfügte das Unternehmen über 156 Forschungsprogramme, die entweder abgeschlossen, in Arbeit oder mit 36 Partnern unter Vertrag sind. AbCellera Biologics Inc. hat eine Forschungskooperation und Lizenzvereinbarung mit Eli Lilly and Company. Das Unternehmen wurde im Jahr 2012 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.